業績

2011年度 :: 学会発表 :: 国際学会 :: 業績

2011 American Institute of Ultrasound in Medicine.
2011.4. New York, USA

<Poster>
Sato T, Akaike J, Toyota J, Karino Y, Ohmura T.
Diagnosis and evaluation of therapeutic effects on rectal varices using percutaneous color Doppler ultrasonography.

The 102th Annual Meeting of American Association for Cancer Research.
2011.4. Oland, USA

<Poster>
Natsuizaka M, Ohashi S, Naganuma S, Kalman RA, Ohyama A, Rhoades B, Vega ME, Stairs, DB, Klein-Szanto AJ, J. Diehl A, Basu D, Herlyn M, Pear WS and Nakagawa H.
Notch regulates squamous differentiation, cell plasticity and tumor heterogeneity in esophageal carcinoma.

The 8th International Gastric Cancer Congress.
2011.4. Soul, Korea

<Poster>
Sasaki T, Yuki S, Kobayashi Y, Kawamoto Y, Nakatsumi H, Sogabe S, Fukushima H, Asaka M, Komatsu Y.
Investigation about AFP (Alpha fetoprotein) Value in Advanced Gastric Cancer.

Digestive Disease Week 2011.
2011.5. Chicago, USA

<Poster>
Ohnishi S, Takeda H, Muto S, Nakagawa K, Sadakane C, Saegusa Y, Nahata M, Hattori T, Asaka M.
Influence of gender on peripheral ghrelin secretion -Examination in the aging mice.

Ohnishi S, Takeda H, Muto S, Nakagawa K, Sadakane C, Saegusa Y, Nahata M, Hattori T, Asaka M.
Potential new treatment to alleviate chemotherapy anorexia.

Kato M, Terao S, Adachi K, Nakajima S, Ando T, Watanabe H, Kato T, Ida K.
Changes of endoscopic gastritis after cure of H. pylori infection.

Muto S, Takeda H, Ohnishi S, Nakagawa K, Sadakane C, Saegusa Y, Nahata M, Hattori T, Asaka M.
Novelty stress-induced anorexia is due to the decrease in the plasma ghrelin level via 5-HT1B/2C-melanocortin-4 system activation.

Muto S, Takeda H, Ohnishi S, Nakagawa K, Sadakane C, Saegusa Y, Nahata M, Hattori T, Asaka M.
Ghrelin resistance in stressed female advanced-age mice.

Takeda H, Muto S, Oridate N, Ohnishi S, Nakagawa K, Sadakane C, Saegusa Y, Nahata M, Hattori T, Asaka M.
Impaired gastric emptying in gastroesophageal reflux disease rat models is caused by a reduced response to ghrelin.

Sato T, Akaike J, Toyota J, Karino Y, Ohmura T.
Endoscopic treatments for gastric antral vascular ectasia associated with chronic liver disease.

European Association for the Study of the Liver.
2011.4. Berlin, Germany

<Poster>
Karino Y, Ozeki I, Toyota J, Imamura M, Tsuge M, Chayama K, Sezaki H, Akuta N, Kumada H.
IL-28B genotype major and relapse of previous PEG-IFN/RBV therapy are the convincing predictor of sustained virological response in telaprevir with PEG-IFN/RBV therapy.

America Society of Clinical Oncology Annual Meeting 2011.
2011.6. Chicago, USA

<Poster>
Agata N, Ueno N, Houzawa H, Ueda E, Komatsu Y, Nishida T, Naito S, Akaza H.
Interim safety results from the all cases post-marketing study (PMS) of sunitinib in 1,027 Japanese patients with renal cell carcinoma (RCC) or gastrointestinal stromal tumor (GIST).

THE 2nd Asia-Pacific Primary Liver Cancer Expert Meeting.
2011.7. Osaka, Japan

<Oral Presentation>
Omura T, Hige S, Terashita K, Nakai M, Horimoto M, Sho T, Nakanishi M, Ogawa K, Chuma M, Sakamoto N, Asaka M.
A case of advanced hepatocellular carcinoma with portal vein tumor thrombus survived over 6 years by multidisciplinary therapy. - Efficacy of hepatoarterial infusion chemotherapy concurrent with radiation -.

The European Multidisciplinary Cancer Congress.
2011.9. Stockholm, Sweden

<Poster>
Komatsu Y, Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Baba H, Tsuji A, Yamaguchi K, Muro K, Ohtsu A.
The Value of Thymidine Kinase 1 (TK1) and Thymidine Phosphorylase (TP) Expression as Predictive Factors With the Treatment Efficacy of TAS-102, a Novel Antitumor Agent, in Patients (pts) With Metastatic Colorectal Cancer (mCRC).

Shimizu Y, Yoshida T, Kato M, Ono S, Homma A, Oridate N, Asaka M.
Screening examination for superficial head and neck cancer in patients who underwent endoscopic resection for squamous cell carcinoma of the esophagus - a recent outcome.

<Oral Presentation>
Kuboki Y, Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Ohtsu A.
A Multicenter, Randomized, Double-Blind, Phase?of TAS-102 (A) plus Best Supportive care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With Chemo-therapy refractory Metastatic Colorectal Cancer (mCRC).

XXIVth International Workshop on Helicobacter and related bacteria in chronic digestive inflammation and gastric cancer.
2011.9. Dublin, Ireland

<Symposium>
Kato M.
9. Recent progress in diagnosis and treatment of early gastric cancer and strategy of elimination of gastric cancer from Japan.

8th APASL single topic conference.
2011.10. Beijing, China

<Poster>
Hige S, Terashita K, Kobayashi T, Horimoto H, Sho T, Nakanishi M, Chuma M.
Serum hepatitis B core-related antigen as a useful marker for the evaluation of antiviral treatment.

United European Gastroenterology Week.
2011.10. Stockholm, Sweden

<Poster>
Mabe K, Kato M, Tanuma T, Nojima M, Yao K*.
Diagnostic accuracy of magnifying endoscopy with Narrow-Band Imaging significantly improves after educational lectures about the “VS” classification system.

Asia Pacific Cancer Conference 2011.
2011.11. Kuala Lumpur, Malaysia

<Poster>
Iwanaga I, Yuki S, Miyagishima T, Hosokawa A, Kato T, Komatsu Y.
Retrospective Cohort Study on the Safety and Efficacy of Bevacizumab for Metastatic Colorectal Cancer Patients:The HGCSG0801 Study - Analysis of Bevacizumab Beyond Progression (BBP) -.

Yuki S, Komatsu Y, Kogawa T, Hatanaka K, Kusumi T, Fujikawa K.
Retrospective Cohort Study on the Safety and Efficacy of Cetuximab for Metastatic Colorectal Cancer Patients The HGCSG0901 Study - Analysis of some predictive markers.

<Oral Presentation>
Kobayashi Y, Yuki S, Hayashi H, Kawamoto Y, Nakatsumi H, Kumagai N, Oba K, Komatsu Y.
Retrospective Cohort study on the risk factors of emergency admissions due to adverse events during chemotherapy for gastric cancer.

62th. Annual Meeting of American Association for the Study of Liver Diseases.
2011.11. San Francisco, USA

<Poster>
Sakamoto N, Tanaka Y, Nakagawa M, Yatsuhashi H, Nishiguchi S, Enomoto N, Azuma S, Nishimura-Sakurai Y, Kakinuma S, Nishida N, Tokunaga K, Mizokami M, Watanabe M.
ITPA gene variant protects against treatment-induced anemia and improves viral clearance by pegylated interferon-alfa and ribavirin therapy in chronic hepatitis C patients.

Kakinuma S, Kamiya A, Sakamoto N, Nakauchi H, Watanabe M.
MMP-2 and MMP-14 derived from donor cells enhance therapeutic efficacy of liver cell transplantation in mice.

Kusano-Kitazume A, Sakamoto N, Okuno Y, Yamamoto M, Sekine-Osajima Y, Nakagawa M, Kakinuma S, Kiyohashi K, Nitta S, Murakawa M, Hagiwara M, Watanabe M.
A high-content screening assay using infectious fluorescence-tagged hepatitis C virus reveals candidates for small molecule inhibitors of viral entry.

Itsui Y, Sakamoto N, Yauchi T, Watanabe M.
Antiviral effect of a novel interferon-inducible protein, IFI-27, against hepatitis C virus replication.

Suda G, Sakamoto N, Itsui Y, Nakagawa M, Tasaka-Fujita M, Funaoka Y, Watanabe T, Nitta S, Kiyohashi K, Azuma S, Kakinuma S, Tsuchiya K, Imamura M, Hiraga N, Chayama K, Watanabe M.
IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones.

Kurosaki M, Itakura J, Yasui Y, Tsuchiya K, Nakanishi H, Takahashi Y, Asahina Y, Tanaka Y, Mizokami M, Sakamoto N, Enomoto N, Izumi N.
Prediction model of ribavirin-induced anemia incorporating ITPA genotype could identify chronic hepatitis C patients at high risk of relapse among virological responders to pegylated-interferon and ribavirin.

Karino Y, Ozeki I, Toyota J, Imamura M, Tsuge M, Chayama K, Akuta N, Suzuki F, Kumada H.
Proposal of response-guide of Triple therapy (PEG/RBV/Telaprevir) using IL28 genotype, Core 70 aa mutation and achievement of RVR in genotype 1b with high viral load patients.

Kobayashi T, Hige S, Terashita K, Nakai M, Horimoto M, Sho T, Nakanishi M, Ogawa K, Chuma M, Sakamoto N, Asaka M.
Anemia and thrombocytosis induced by ribavirin monotherapy for patients with chronic hepatitis C.

<Oral Presentation>
Kiyohashi K, Kakinuma S, Kamiya A, Sakamoto N, Nakauchi H, Watanabe M.
Loww of Wnt5A promotes biliary differentiation of murine hepatic stem/progenitor cells."

Gastrointestinal Cancers Symposium.
2012.1. San Francisco, USA

<Poster>
Nishina T, Sawaki A, Yamada Y, Yamaguchi K, Doi T, Chin K, Satoh T, Boku N, Omuro Y, Komatsu Y, Takiuchi H, Hamamoto Y, Koizumi W, Saji S, M A. Shah, E Van Cutsem, Y-K Kang, Ohtsu A.
Regional differences in patient (pt) characteristics of AVAGAST: An exploratory comparison in chemotherapy plus placebo (PL) arm between Japanese (JPN) and the rest of the world (ROW) pts.

Kawamoto Y, Yuki S, Kobayashi Y, Oba K, Hayashi H, Nakatsumi H, Komatsu Y.
Retrospective cohort study on the risk factors of admission due to serious adverse events during S-1 (tegaful, gimeracil, oteracil potassium) containing chemotherapy for gastric cancer.

Nishina T, Yoshino T, Mizunuma N, Yamazaki K, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Ohtsu A.
Therapeutic effect of TAS-102 (A) in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy by the K▲hne model (Km).

Sogabe S, Yuki S, Hayashi H, Naruse H, Nakamura M, Iwanaga I, Kato T, Takagi T, Okuda H, Komatsu Y.
Retrospective cohort study on the safety and efficacy of bevacizumab for metastatic colorectal cancer patients: The HGCSG0801 study-Efficacy of KRAS mutational status.

Yamazaki K, Naito Y, Yuki S, Kawamoto Y, Yasui H, Takano T, Komatsu Y, Muro K, Shitara K.
Validation study of a prognostic classification system in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.

Yuki S, Komatsu Y, Kawamoto Y, Tsuji Y, Naruse H, Hosokawa A, Kusumi T, Ishiguro A, Saito S, Sakata Y.
Retrospective Cohort Study on the Safety and Efficacy of Cetuximab for Metastatic Colorectal Cancer Patients: The HGCSG0901 Study - Analysis of after Cetuximab refractory -.

Hatanaka K, Yuki S, Nakatsumi H, Kogawa T, Fukushima H, Fujikawa K, Sato Y, Saito M, Munakata M, Komatsu Y.
Retrospective Cohort Study on the Safety and Efficacy of Cetuximab for Metastatic Colorectal Cancer Patients: The HGCSG0901 Study - Analysis of some predictive markers -.

Fukushima H, Yuki R, Kobayashi Y, Hatanaka K, Kusumi T, Hosokawa A, Miyagishima T, Takeuchi S, Kudo M, Komatsu Y.
Retrospective Cohort Study on the Safety and Efficacy of Bevacizumab for Metastatic Colorectal Cancer Patients: The HGCSG0801 Study - Analysis of Bevacizumab Beyond Progression (BBP) -."

The Asian Pacific Association for the Study of the Liver.
2012.2. Taipei, Taiwan

<Poster>
Karino Y, Toyota J, Ohmura T, Ikeda K, Suzuki Y, Chayama K, Takahashi S, Kawakami Y, Kumada H.
Dual oral therapy with the NS5A inhibitor Daclatasvir (BMS-790052) and the NS3 protease inhibitor Asunaprevir (BMS-650032) in HCV genotype 1b-infected null responders or patients ineligible/intolerant to Peginterferon/Ribavirin.

>